Suzetrigine vs VX-993
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Diabetic Peripheral Neuropathic Pain
Shared mechanism: Voltage-gated sodium channel NaV1.8 · full Diabetic Peripheral Neuropathic Pain pipeline
Suzetrigine · Journavx
Marketed by Vertex Pharmaceuticals
NCT05660538 · Phase 2 · completed
The trial randomized 194 participants to three suzetrigine doses or active-controlled pregabalin, using quadruple blinding and matched placebos; the primary endpoint was the clinical symptom measure of change in weekly average pain score. The reported within-group pain changes were similar across arms, but statistical significance for the between-group primary comparisons is not provided, so the result is unclear rather than definitively met.
Next expected readout: January 2027 · NCT06696443 (registry estimate)
Reported efficacy
Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS) (Baseline, At Week 12): Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS) (Baseline, At Week 12): Pregabalin -2.09 units on a scale (95% CI -2.65--1.52) vs Suzetrigine (SUZ): Low Dose -2.18 units on a scale (95% CI -2.94--1.41) vs Suzetrigine (SUZ): Mid Dose -2.11 units on a scale (95% CI -2.67--1.55) vs Suzetrigine (SUZ): High Dose -2.26 units on a scale (95% CI -2.82--1.70) (unclear)
Result source: NCT05660538
VX-993
Developed by Vertex Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT06619860 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Diabetic Peripheral Neuropathic Pain
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Suzetrigine | VX-993 |
|---|---|---|
| Average daily pain, change | -2.2 vs -2.1vs PregabalinNCT056605382 other results
| —Not reported |
| 30% pain reduction | 70.8% vs 44.9%vs PregabalinNCT056605382 other results
| —Not reported |
| 50% pain reduction | 41.7% vs 22.4%vs PregabalinNCT056605382 other results
| —Not reported |
| Sleep interference, change | -2.2 vs -2.4vs PregabalinNCT056605382 other results
| —Not reported |
Average daily pain, change
- Suzetrigine
- -2.2 vs -2.1vs PregabalinNCT05660538
2 other results
- -2.1 vs -2.1 NCT05660538
- -2.3 vs -2.1 NCT05660538
- VX-993
- —Not reported
30% pain reduction
- Suzetrigine
- 70.8% vs 44.9%vs PregabalinNCT05660538
2 other results
- 46% vs 44.9% NCT05660538
- 48% vs 44.9% NCT05660538
- VX-993
- —Not reported
50% pain reduction
- Suzetrigine
- 41.7% vs 22.4%vs PregabalinNCT05660538
2 other results
- 32% vs 22.4% NCT05660538
- 34% vs 22.4% NCT05660538
- VX-993
- —Not reported
Sleep interference, change
- Suzetrigine
- -2.2 vs -2.4vs PregabalinNCT05660538
2 other results
- -2.4 vs -2.4 NCT05660538
- -2.1 vs -2.4 NCT05660538
- VX-993
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
VX-993: no structured comparison results are available for Diabetic Peripheral Neuropathic Pain.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Suzetrigine: 4 of 4 rows · VX-993: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Suzetrigine |
|---|---|
| Dropout rate | 16.1%High Dosea NCT05660538 · Phase 2 |
| Discontinued due to AEs | 0%High Dosea NCT05660538 · Phase 2 |
| Serious AEs | 1.8%High Dosea NCT05660538 · Phase 2 |
| Most frequent reported AEs | show 2 more resultsLow Dose back pain 10.7% oedema peripheral 3.6% creatinine renal clearance decreased 0% NCT05660538 · Phase 2 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Suzetrigine
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Suzetrigine's landscape · VX-993's landscape